VST's rising earnings outlook, strong ROE and faster sales growth sharpen its edge in a head-to-head comparison with SO.

HOUSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Standards Core LLC today announced the availability of Standards + Excelerate Copilots in the Microsoft Marketplace. These add-ins for Microsoft Word and Microsoft Excel empower technical and legal documents with safe, redundant, self-verifying, and iterative AI.

Renewable fuel and specialty alcohol producer Alto Ingredients reported strong third quarter results with profitability well ahead of consensus expectations: Key performance indicators like gross margin, adjusted EBITDA and free cash flow surged to new multi-year highs. Results benefited from a combination of seasonal strength, favorable export pricing, strong CO2 demand and benefits from the company's recent cost reduction and efficiency improvement initiatives.

Camden Property Trust faces headwinds from falling rents and weak Sun Belt demand, but maintains resilient performance and disciplined expense management. CPT delivered solid Q3 results, with FFO in line, modest revenue growth, and a strong balance sheet supporting buybacks and a 4% dividend yield. While near-term rental growth remains sluggish, CPT's focus on renewals, low turnover, and declining supply position it for eventual rent recovery.

Mexico's President Claudia Sheinbaum has sweet-talked U.S. President Donald Trump while Canadian Prime Minister Mark Carney has used tougher talk. Both markets have outperformed.

ZM's Q3 results top estimates as earnings and revenues rise year over year, fueled by Enterprise gains, expanding margins and stronger cash flow performance.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Atmos (ATO) have what it takes?

Nvidia ( NASDAQ:NVDA ) has ridden the AI wave to unprecedented heights.

Our global markets watchlist tracks nine prominent indexes from economies around the world.

Transaction in Own Shares 25 November, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company') announces that on 25 November, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency 25/11/2025 748,395 27.9850 27.5400 27.7619 LSE GBP 25/11/2025 - - - - Chi-X (CXE) GBP 25/11/2025 - - - - BATS (BXE) GBP 25/11/2025 750,087 31.9500 31.4500 …

Zoom Communications Inc (NASDAQ: ZM) reported better-than-expected financial results for the third quarter after the market close on Monday.

Investors interested in Mining - Gold stocks are likely familiar with Centerra Gold Inc. (CGAU) and Agnico Eagle Mines (AEM). But which of these two companies is the best option for those looking for undervalued stocks?

CNBC's Deirdre Bosa joins 'Squawk on the Street' to report on Meta as the social media giant is exploring the use of Google AI chips.

Investors looking for stocks in the Retail - Apparel and Shoes sector might want to consider either Gap (GAP) or Deckers (DECK). But which of these two stocks offers value investors a better bang for their buck right now?

Investors looking for stocks in the Tobacco sector might want to consider either Universal Corp. (UVV) or British American Tobacco (BTI). But which of these two stocks presents investors with the better value opportunity right now?

Investors looking for stocks in the Security and Safety Services sector might want to consider either Alarm.com Holdings (ALRM) or Assa Abloy AB (ASAZY). But which of these two companies is the best option for those looking for undervalued stocks?

Investors with an interest in Utility - Electric Power stocks have likely encountered both FirstEnergy (FE) and American Electric Power (AEP). But which of these two companies is the best option for those looking for undervalued stocks?

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs should be tested to prevent the disease in people at risk.

The U.K.'s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc's (NASDAQ: AUTL) Aucatzyl (obecabtagene autoleucel, or obe-cel) for use in the National Health Service (NHS) for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

SU's record output, strong margins and disciplined capital returns support a hold stance, even as commodity risks and regulatory pressures linger.